Do analysts rate APLM or IMRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, APLM or IMRN?

Immuron has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.66 -$10.94M N/A N/A Immuron $5.47M 1.76 -$2.61M N/A N/A

Is APLM or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Immuron N/A N/A N/A

Do analysts prefer MCRB or IMRN?

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 303.80%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Seres Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, MCRB or IMRN?

Seres Therapeutics has higher earnings, but lower revenue than Immuron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seres Therapeutics $790K 53.56 $5.70M -$2.43 N/A Immuron $5.47M 1.76 -$2.61M N/A N/A

Do analysts prefer IMMP or IMRN?

Prima BioMed currently has a consensus price target of $5.50, suggesting a potential upside of 1,581.96%. Given Prima BioMed's stronger consensus rating and higher probable upside, equities analysts plainly believe Prima BioMed is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, IMMP or IMRN?

Immuron has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 2.94 -$53.82M N/A N/A Immuron $5.47M 1.76 -$2.61M N/A N/A

Is IMMP or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Immuron N/A N/A N/A

Do analysts recommend IMRN or ANVS?

Annovis Bio has a consensus target price of $12.00, indicating a potential upside of 1,016.28%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable valuation and earnings, IMRN or ANVS?

Immuron has higher revenue and earnings than Annovis Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $5.47M 1.76 -$2.61M N/A N/A Annovis Bio N/A N/A -$28.85M -$1.79 N/A

Is IMRN or ANVS more profitable?

Immuron's return on equity of 0.00% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A Annovis Bio N/A -685.98% -258.77%

Do analysts recommend TIL or IMRN?

Instil Bio presently has a consensus price target of $7.00, indicating a potential downside of 2.51%. Given Instil Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Instil Bio is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TIL or IMRN?

Immuron has higher revenue and earnings than Instil Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$4.47 N/A Immuron $5.47M 1.76 -$2.61M N/A N/A

Is TIL or IMRN more profitable?

Immuron's return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% Immuron N/A N/A N/A

Immuron (IMRN) Competitors

$1.19 -0.05 (-4.03%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$1.16 -0.02 (-2.10%)

As of 04:31 AM Eastern

Compare

IMRN vs. APLM, MCRB, IMMP, ANVS, and TIL

Should you buy Immuron stock or one of its competitors? Immuron's main competitors and comparable companies include Apollomics (APLM), Seres Therapeutics (MCRB), Prima BioMed (IMMP), Annovis Bio (ANVS), and Instil Bio (TIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immuron compare to Apollomics?

Apollomics (NASDAQ:APLM) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

19.1% of Apollomics shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Immuron	N/A	N/A	N/A

Immuron has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.66	-$10.94M	N/A	N/A
Immuron	$5.47M	1.76	-$2.61M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Immuron has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

In the previous week, Apollomics had 1 more articles in the media than Immuron. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for Immuron. Apollomics' average media sentiment score of 0.94 equaled Immuron'saverage media sentiment score.

Company	Overall Sentiment
Apollomics	Positive
Immuron	Positive

Summary

Apollomics beats Immuron on 5 of the 7 factors compared between the two stocks.

How does Immuron compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immuron has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Immuron's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Immuron	N/A	N/A	N/A

Seres Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Immuron has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

In the previous week, Seres Therapeutics and Seres Therapeutics both had 1 articles in the media. Seres Therapeutics' average media sentiment score of 1.87 beat Immuron's score of 0.94 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seres Therapeutics	Very Positive
Immuron	Positive

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 303.80%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Seres Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Seres Therapeutics has higher earnings, but lower revenue than Immuron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	53.56	$5.70M	-$2.43	N/A
Immuron	$5.47M	1.76	-$2.61M	N/A	N/A

Summary

Seres Therapeutics beats Immuron on 7 of the 13 factors compared between the two stocks.

How does Immuron compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Immuron has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	2.94	-$53.82M	N/A	N/A
Immuron	$5.47M	1.76	-$2.61M	N/A	N/A

Prima BioMed currently has a consensus price target of $5.50, suggesting a potential upside of 1,581.96%. Given Prima BioMed's stronger consensus rating and higher probable upside, equities analysts plainly believe Prima BioMed is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Immuron has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

In the previous week, Prima BioMed had 2 more articles in the media than Immuron. MarketBeat recorded 3 mentions for Prima BioMed and 1 mentions for Immuron. Immuron's average media sentiment score of 0.94 beat Prima BioMed's score of -0.04 indicating that Immuron is being referred to more favorably in the news media.

Company	Overall Sentiment
Prima BioMed	Neutral
Immuron	Positive

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Immuron	N/A	N/A	N/A

Summary

Prima BioMed beats Immuron on 8 of the 11 factors compared between the two stocks.

How does Immuron compare to Annovis Bio?

Immuron (NASDAQ:IMRN) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Annovis Bio had 2 more articles in the media than Immuron. MarketBeat recorded 3 mentions for Annovis Bio and 1 mentions for Immuron. Immuron's average media sentiment score of 0.94 beat Annovis Bio's score of 0.76 indicating that Immuron is being referred to more favorably in the media.

Company	Overall Sentiment
Immuron	Positive
Annovis Bio	Positive

0.1% of Immuron shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immuron has higher revenue and earnings than Annovis Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$5.47M	1.76	-$2.61M	N/A	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Immuron's return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Annovis Bio	N/A	-685.98%	-258.77%

Immuron has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Annovis Bio has a consensus target price of $12.00, indicating a potential upside of 1,016.28%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Annovis Bio beats Immuron on 7 of the 12 factors compared between the two stocks.

How does Immuron compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immuron's return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
Immuron	N/A	N/A	N/A

Instil Bio has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Immuron has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Immuron has higher revenue and earnings than Instil Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
Immuron	$5.47M	1.76	-$2.61M	N/A	N/A

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.89 beat Immuron's score of 0.94 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Immuron	Positive

Instil Bio presently has a consensus price target of $7.00, indicating a potential downside of 2.51%. Given Instil Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Instil Bio is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Instil Bio beats Immuron on 6 of the 10 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRN vs. The Competition

Export

Metric	Immuron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.01M	$3.85B	$7.23B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	N/A	14.33	273.87	25.33
Price / Sales	1.76	1,409.16	643.23	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	1.28	15.27	10.37	6.24
Net Income	-$2.61M	-$22.78M	$3.49B	$358.55M
7 Day Performance	-26.99%	-2.50%	-0.75%	-1.17%
1 Month Performance	10.19%	-2.83%	-1.31%	-4.26%
1 Year Performance	-35.50%	37.96%	21.17%	5.47%

Immuron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRN Immuron	0.7669 of 5 stars	$1.19 -4.0%	N/A	-35.6%	$10.01M	$5.47M	N/A	N/A	Gap Down
APLM Apollomics	1.722 of 5 stars	$24.39 -0.4%	N/A	+79.6%	$53.57M	$8.50M	N/A	45	Upcoming Earnings Gap Down
MCRB Seres Therapeutics	3.5213 of 5 stars	$5.28 -5.0%	$17.00 +222.0%	-75.8%	$53.06M	$790K	N/A	330	News Coverage Positive News
IMMP Prima BioMed	1.4537 of 5 stars	$0.36 -2.7%	$5.50 +1,448.9%	-80.7%	$52.33M	$16.40M	N/A	2,021	Gap Up
ANVS Annovis Bio	2.5016 of 5 stars	$1.23 -5.5%	$12.00 +877.2%	-54.9%	$52.32M	N/A	N/A	3	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRN) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuron (IMRN) Competitors